Bristol-Myers Squibb
This article was originally published in The Tan Sheet
Executive Summary
Exec VP and Chief Financial Officer Michael Autera will assume responsibility for the Mead Johnson nutritionals business as well as BMS' medical device units Convatec, Zimmer and Linvatec, effective Jan. 1. Autera will remain CFO until a replacement is named. In addition, Senior VP William Flatley "will assume responsibility for business strategy, the company's productivity enhancement initiatives and coordination of the restructuring effort of the corporate staff organization," BMS said. Flatley will continue to be responsible for corporate hospital accounts. Both Autera and Flatley will report to President Charles Heimbold, who becomes CEO on Jan. 1.